Results 131 to 140 of about 183,390 (190)

Clinical Efficacy of the HIV Protease Inhibitor Indinavir in Combination with Chemotherapy for Advanced Classic Kaposi Sarcoma Treatment: A Single-Arm, Phase II Trial in the Elderly. [PDF]

open access: yesCancer Res Commun
Sgadari C   +12 more
europepmc   +1 more source

Diastereoselective Synthesis of the HIV Protease Inhibitor Darunavir and Related Derivatives via a Titanium Tetrachloride-Mediated Asymmetric Glycolate Aldol Addition Reaction. [PDF]

open access: yesJ Org Chem
Witte JM   +11 more
europepmc   +1 more source

Analysis of drug resistance in HIV protease. [PDF]

open access: yesBMC Bioinformatics, 2018
Pawar SD   +3 more
europepmc   +1 more source

Combination antiretroviral therapy and the risk of myocardial infarction [PDF]

open access: yes, 2003
Abbadesse, V   +535 more
core  

HIV protease inhibitors

AIDS, 1996
The protease encoded by the human immunodeficiency virus (HIV protease) mediates the maturation of newly formed HIV particles through proteolytic processing of the gag and gag-pol gene products. Because of its essential role in the HIV replication cycle, this enzyme represents a logical target for the treatment of HIV infection.
A, Carr, D A, Cooper
  +7 more sources

HIV-Protease Inhibitors

New England Journal of Medicine, 1998
Inhibitors of human immunodeficiency virus (HIV)–encoded protease, combined with nucleoside analogues with antiretroviral activity, cause profound and sustained suppression of viral replication, reduce morbidity, and prolong life in patients with HIV infection.1–3 Recent guidelines recommend that initial treatment of all HIV-infected patients include ...
G. Di Perri   +2 more
  +6 more sources

Heterocyclic HIV-Protease Inhibitors

Current Medicinal Chemistry, 2013
In the panorama of HIV protease inhibitors (HIV PIs), many efforts have been devoted to the development of new compounds with reduced peptidic nature in order to improve pharmacokinetics and pharmacodynamics features. The introduction of cyclic scaffolds in the design of new chemical entities reduces flexibility and affords more rigid inhibitors ...
CALUGI, CHIARA   +2 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy